A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2017 Status changed from recruiting to discontinued due to poor accural.
- 18 Jun 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.